1NM-PP1
CAS No. 221244-14-0
1NM-PP1 ( PP1 Analog II )
产品货号. M13527 CAS No. 221244-14-0
1NM-PP1(PP1 Analog II) 是一种细胞渗透性 PP1 类似物,可作为突变激酶对其野生型祖细胞的有效和选择性抑制剂 (IC50=28 uM vSrc; 4.2 nM v-Src-as1 I338G)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥436 | 有现货 |
|
| 5MG | ¥696 | 有现货 |
|
| 10MG | ¥1074 | 有现货 |
|
| 25MG | ¥2223 | 有现货 |
|
| 50MG | ¥3506 | 有现货 |
|
| 100MG | ¥4851 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥751 | 有现货 |
|
生物学信息
-
产品名称1NM-PP1
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述1NM-PP1(PP1 Analog II) 是一种细胞渗透性 PP1 类似物,可作为突变激酶对其野生型祖细胞的有效和选择性抑制剂 (IC50=28 uM vSrc; 4.2 nM v-Src-as1 I338G)。
-
产品描述1NM-PP1(PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors(IC50=28 uM vSrc; 4.2 nM v-Src-as1 I338G).
-
体外实验Cdk7 from Cdk7as/as or Cdk7+/+ cells is immunoprecipitated and tested its kinase activity towards both a Pol II CTD-containing fusion protein (GST-CTD) and human Cdk2. Cdk7 recovered from the mutant, but not the wild-type, cells is inhibited by 1-NM-PP1 (1-NMPP1), with an IC50 of ~50 nM with either substrate. Replacement of wild-type Cdk7 with Cdk7as/as also rendered growth of HCT116 cells sensitive to 1-NM-PP1. In the absence of 1-NM-PP1, the wild-type andCdk7as/as cells had population doubling times of ~17.9 and ~20.2 h, respectively, with similar cell-cycle distributions in asynchronous culture, indicating minimal impairment of Cdk7 function by the F91G mutation per se. The homozygous Cdk7as/as cells are sensitive to 1-NM-PP1, however, with an IC50 ~100 nM measured by cell viability (MTT) assays performed after 96 h of 1-NM-PP1 exposure. In contrast, wild-type HCT116 cells are resistant to 10 μM 1-NM-PP1. Addition of 10 μM 1-NM-PP1 retards G1/S progression by the mutant but not the wild-type cells. When added simultaneously with serum to the Cdk7as/as cells, 1-NM-PP1 prevents any progression into S phase in the next 15 h. After 24 h, there is evidence of progression into S-phase by a fraction of Cdk7as/as cells released from serum starvation directly into medium containing 1-NM-PP1, while a fraction remained in G1. The addition of 1-NM-PP1 3 h or 6 h after serum addition delays S-phase entry by ~7 h or by ~3 h, respectively.
-
体内实验——
-
同义词PP1 Analog II
-
通路Angiogenesis
-
靶点CDK
-
受体CDK7
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number221244-14-0
-
分子量331.41
-
分子式C20H21N5
-
纯度>98% (HPLC)
-
溶解度DMSO: 10 mM
-
SMILESNC1=C2C(N(C(C)(C)C)N=C2CC3=C4C=CC=CC4=CC=C3)=NC=N1
-
化学全称1-(tert-butyl)-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Papa FR, et al. Science. 2003 Nov 28;302(5650):1533-7.
产品手册
关联产品
-
NU-6102
一种有效的 CDK1 和 CDK2 抑制剂,对 CDK1/cyclinB 和 CDK2/cyclinA3 的 IC50 分别为 9.5 nM 和 5.4 nM。
-
SEL120-34A hydrochlo...
SEL120-34A 是一种 ATP 竞争性、选择性、口服活性 CDK8 抑制剂,可抑制 CDK8/CycC 和 CDK19/CycC 复合物的激酶活性,IC50 分别为 4.4 nM 和 10.4 nM。
-
CDK4/6-IN-2
CDK4/6-IN-2 是一种有效的 CDK4 和 CDK6 抑制剂(IC50:2.7 和 16 nM),源自专利 US20180000819A1(化合物 1)。
021-51111890
购物车()
sales@molnova.cn

